Renaissance Technologies LLC Decreases Stock Position in ICU Medical, Inc. $ICUI

Renaissance Technologies LLC cut its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 68.8% in the first quarter, Holdings Channel reports. The institutional investor owned 11,309 shares of the medical instruments supplier’s stock after selling 24,991 shares during the period. Renaissance Technologies LLC’s holdings in ICU Medical were worth $1,461,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sei Investments Co. raised its stake in shares of ICU Medical by 40.8% in the first quarter. Sei Investments Co. now owns 48,632 shares of the medical instruments supplier’s stock valued at $6,281,000 after acquiring an additional 14,093 shares during the period. Lido Advisors LLC boosted its stake in shares of ICU Medical by 17.4% during the 1st quarter. Lido Advisors LLC now owns 2,910 shares of the medical instruments supplier’s stock worth $376,000 after purchasing an additional 431 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of ICU Medical by 2.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,519 shares of the medical instruments supplier’s stock worth $584,000 after purchasing an additional 125 shares during the period. Madison Asset Management LLC bought a new position in ICU Medical during the 1st quarter valued at about $2,333,000. Finally, Dimensional Fund Advisors LP raised its position in ICU Medical by 6.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock worth $127,053,000 after purchasing an additional 63,026 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Price Performance

ICU Medical stock opened at $179.34 on Thursday. The stock has a market cap of $4.48 billion, a price-to-earnings ratio of 151.98, a price-to-earnings-growth ratio of 2.54 and a beta of 0.74. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. ICU Medical, Inc. has a 1 year low of $110.50 and a 1 year high of $192.85. The firm has a 50-day moving average of $154.67 and a two-hundred day moving average of $141.46.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same period last year, the company posted $2.10 earnings per share. The company’s quarterly revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, research analysts forecast that ICU Medical, Inc. will post 6.51 earnings per share for the current year.

Key ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Strong earnings and margin expansion support the investment case. ICU Medical’s latest quarterly results exceeded expectations, with EPS of $2.37 versus the $1.91 consensus and revenue of $547.88 million versus estimates of $533.44 million. A recent analysis also highlighted margin expansion and strength in the company’s infusion systems business. ICUI Q2 Deep Dive: Margin Expansion and Infusion Systems Drive Outperformance
• Positive Sentiment: Analysts raised price targets following the results. Needham lifted its target to $187, BTIG raised its target to $200, and Piper Sandler increased its target to $195 while maintaining an overweight rating. The consensus rating remains “Moderate Buy,” with an average price target of $192.80.
• Neutral Sentiment: Institutional ownership remains high. Several smaller investment firms recently initiated or increased positions in ICU Medical, while institutional investors and hedge funds collectively own approximately 96.1% of the shares. The reported short-interest data showed zero shares short, offering little indication of short-selling pressure.
• Negative Sentiment: Multiple insiders sold shares near recent highs. COO Christian B. Voigtlander sold 8,929 shares for approximately $1.63 million, CIO Ben Sousa sold 2,250 shares for about $401,000, and Director Elisha Finney sold 378 shares for roughly $69,000. The sales reduced their respective holdings by approximately 19.3%, 42.3% and 7.2%, potentially raising investor concerns about insider conviction. Top ICU Medical Executive Makes a Notable Move With Company Stock

Wall Street Analysts Forecast Growth

ICUI has been the subject of several recent analyst reports. Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. KeyCorp raised their price target on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 21st. Weiss Ratings upgraded ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Finally, Needham & Company LLC upped their price objective on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $192.80.

Insider Buying and Selling

In other ICU Medical news, Director Elisha W. Finney sold 378 shares of ICU Medical stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total transaction of $68,977.44. Following the completion of the sale, the director directly owned 4,871 shares of the company’s stock, valued at $888,860.08. The trade was a 7.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Christian B. Voigtlander sold 8,929 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total value of $1,633,381.97. Following the completion of the sale, the chief operating officer owned 37,377 shares of the company’s stock, valued at $6,837,374.61. This represents a 19.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 11,557 shares of company stock valued at $2,103,579 over the last quarter. 2.10% of the stock is owned by corporate insiders.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.